EAU 2008 - Advances in Targeted Therapy and Tissue Engineering in Urology: Targeted Therapy
Tuesday, 01 April 2008
MILAN, ITALY (UroToday.com) - When a patient comes to the pharmacist in the future he may state: “Here is my sequence”. This could be a consequence of the development of targeted therapies as presented by Chris Evans. He pointed out that molecular profile of a patient will have an increasing impact on the selection patients for a diagnostic procedure or even a specific therapy.
Login to read more...
|
EAU 2008 - Research Shows Elevated Serum Amyloid Alpha (SAA-1) Levels in Renal Cell Cacinoma Patients
Tuesday, 08 April 2008
MILAN, ITALY (UroToday.com) - Serum amyloid alpha 1 (SAA-1) was measured in serum of 62 patients with renal cell carcinoma (RCC) and compared to healthy volunteers as well as patients with prostate cancer or bladder cancer (n=54).
Login to read more...
|
EAU 2008 - Advances in Targeted Therapy and Tissue Engineering in Urology
Tuesday, 01 April 2008
MILAN, ITALY (UroToday.com) - Dr. Evans (Sacramento) presented a lecture on targeted therapies. Most drugs have a mechanistic “target”, such as the enzymes 5-α reductase in the treatment of BPH or 5-phosphodiesterase in the treatment of erectile dysfunction. However, in the current presentation, “targeted therapy” is defined as molecular targeting.
Login to read more...
|
EAU 2008 - Optical Coherence Tomography (OCT) Helps Distinguish Normal Renal Parenchyma from Renal Cancer Tissue
Tuesday, 08 April 2008
MILAN, ITALY (UroToday.com) - Optical coherence tomography (OCT) was shown to distinguish normal renal parenchyma from tumor tissue in 20 patients undergoing partial nephrectomy.
Login to read more...
|
EAU 2008 - The Use of Biological Markers in Clinical Practice
Tuesday, 01 April 2008
MILAN, ITALY (UroToday.com) - Dr. Bjartell (Lund) presented on the use of biological markers as they can apply to clinical practice. A useful biomarker, he said is a molecular test that provides additional information to clinical information.
Login to read more...
|
EAU 2008 - Technology Makes the Single-Port Laparoscopic Nephrectomy Possible
Tuesday, 08 April 2008
MILAN, ITALY (UroToday.com) - Laparoscopic nephrectomy can be performed via one port.
Login to read more...
|
EAU 2008 - Vitespen Vaccine Demonstrates Possible Benefit for a Specific Subgroup of Renal Cancer Patients
Tuesday, 08 April 2008
MILAN, ITALY (UroToday.com) - An autologous heat shock peptide vaccine called Vitespen demonstrated a possible benefit for a specific subgroup of patients in a randomized open phase-III trial.
Login to read more...
|
EAU 2008 - Molecular Detection of Lymph Node Involvement in Genitourinary Cancer
Tuesday, 01 April 2008
MILAN, ITALY (UroToday.com) - Dr. Michael Jewett (Toronto) presented the SIU lecture on detection and mapping regional lymph nodes (LN) in genitourinary cancer. He addressed the importance of LN in staging and therapy of GU cancers.
Login to read more...
|
EAU 2008 - Sorafenib Versus Placebo as a Second Line Therapy of Metastatic Renal Cell Carcinoma (RCC)
Tuesday, 08 April 2008
MILAN, ITALY (UroToday.com) - The randomized phase-III TARGETs trial compared Sorafenib versus Placebo as second line therapy of metastatic renal cell carcinoma (RCC).
Login to read more...
|
EAU 2008 - Nephron-Sparing Surgery Should be Systematically Considered Regardless of Tumor Size
Tuesday, 08 April 2008
MILAN, ITALY (UroToday.com) - Nephron-sparing surgery is equivalent to radical nephrectomy in terms of cancer-specific survival.
Login to read more...
|
EAU 2008 - Perioperative Use and Surgical Complications of Sunitinib in Metastatic Renal Cell Carcinoma
Friday, 04 April 2008
MILAN, ITALY (UroToday.com) - These investigators evaluated their postoperative complication rate in patients having metastatic renal adenocarcinoma and treated with Sunitinib during the perioperative period.
Login to read more...
|
EAU 2008 - Zoledronic Acid is Cost-Saving and Improves Quality Adjusted Survival in the Prevention of Skeletal Related Events in Patients with Bone Metastases Secondary to Advanced Renal Cell Carcinoma (RCC)
Friday, 04 April 2008
MILAN, ITALY (UroToday.com) - A United Kingdom (UK) Perspective
Login to read more...
|
EAU 2008 - Laparoscopic High-Intensity Focused Ultrasound for Energy Ablative Therapy of Small Renal Tumors
Thursday, 03 April 2008
MILAN, ITALY (UroToday.com) - A group from the Medical University of Vienna, Austria presented their data on high-intensity focused ultrasound (HIFU) for the treatment of small renal tumors.
Login to read more...
|
EAU 2008 - Laparoscopic Renal Cryoablation (LRC) of Small Renal Masses
Thursday, 03 April 2008
MILAN, ITALY (UroToday.com) - Lessons Learned from 104 Cases in a 7-year Experience
Login to read more...
|
EAU 2008 - The Clinical Significance of Micro-Metastatic Lymph Node Disease in Kidney and Bladder Cancer
Tuesday, 01 April 2008
MILAN, ITALY (UroToday.com) - Dr. Gschwend (Munich) presented a State-of-the-Art lecture on LN disease in renal and bladder cancers. He began with bladder cancer and that staging correlates with disease specific survival.
Login to read more...
|
EAU 2008 - Radical Nephrectomy is not Superior to Nephron Sparing Surgery in pT1b-pT2N0M0 Renal Tumors
Thursday, 03 April 2008
MILAN, ITALY (UroToday.com) - A Matched Comparison Analysis in 546 Cases
Login to read more...
|
EAU 2008 - Surgical Management Safety and Short-Term Efficacy of Laparoscopic Cryoablation for Renal Tumors ≥ 3 cm: A Multicenter European Report
Thursday, 03 April 2008
MILAN, ITALY (UroToday.com) - A multicenter European group reported on the short-term outcomes of laparoscopic cryoablation for renal lesions greater than 3cm in size. Laparoscopic cryoablation has previously been reported as safe and effective for renal tumors
Login to read more...
|
EAU 2008 - Surgical Management - Scarless Nephrectomy by Transgastric and Transvesical Combined Approach
Thursday, 03 April 2008
MILAN, ITALY (UroToday.com) - Dr. Lima from Porto, Portugal presented the novel concept of “natural orifices translumenal endoscopic surgery” (NOTES) as applied to nephrectomy in an experimental model.
Login to read more...
|
EAU 2008 - A Large Open-Label, Non-Comparative, Phase III Study of the Multi-Targeted Kinase Inhibitor Sorafenib in European Patients with Advanced Renal Cell Carcinoma
Thursday, 03 April 2008
MILAN, ITALY (UroToday.com) - Dr. Verzoni presented a trial to collect safety and efficacy data on sorafenib from a large and broad study population reflecting clinical practice.
Login to read more...
|
EAU 2008 - A Multicenter, Randomized, Phase 3 Trial of a Novel, Autologous, Therapeutic Vaccine (Vitespen) vs. Observation as Adjuvant Therapy in Patients at High Risk of Recurrence after Nephrectomy for Renal Cell Carcinoma
Thursday, 03 April 2008
MILAN, ITALY (UroToday.com) - Representing an international group of researchers, Dr. Peter Mulders reported on the activity of vitespen (autologous, tumor-derived heat shock protein gp96-peptide complexes) in patients at high risk of recurrence after resection of locally advanced renal cell carcinoma (RCC) compared with no adjuvant treatment (observation).
Login to read more...
|
EAU 2008 - Sorafenib in Advanced Renal Cell Carcinoma (RCC): Survival and Biomarker Results from a Phase III Trial
Wednesday, 02 April 2008
MILAN, ITALY (UroToday.com) - Dr. Porta presented this talk on behalf of the sorafenib (Sor) TARGET clinical trial group.
Login to read more...
|
EAU 2008 - Safety and Efficacy of Sunitinib in an Expanded-Access Trial of Metastatic Renal Cell Carcinoma (mRCC): Updated Results and Subpopulation Analysis
Wednesday, 02 April 2008
MILAN, ITALY (UroToday.com) - Sunitinib malate is an oral, multi-targeted tyrosine kinase inhibitor with direct anti-tumor and anti-angiogenic activities, internationally approved for the first-line treatment of advanced RCC. This international, open-label trial was undertaken to provide sunitinib to patients (pts) with advanced RCC who might benefit from therapy, but who had no access to the drug prior to regulatory approval in their countries.
Login to read more...
|
EAU 2008 - Sorafenib Monotherapy in Patients with Metastatic Renal Cell Cancer: A Phase II Intra-Patient Dose Escalation Study
Wednesday, 02 April 2008
MILAN, ITALY (UroToday.com) - Sorafenib 400 mg b.i.d. has shown anti-tumor activity and favorable tolerability in patients with metastatic renal cell carcinoma (RCC), allowing investigation of more intensive drug administration regimens. This titration study allowed individual patients to escalate to higher doses of sorafenib. Trial endpoints included response rate (RR), progression-free survival (PFS) and overall survival (OS).
Login to read more...
|
EAU 2008 - Sorafenib Plus Interferon-α2a in Metastatic Renal Cell Carcinoma: Results from RAPSODY (GOIRC Study 0681) - A Randomized Prospective Phase II Trial of Two Different Treatment Schedules
Wednesday, 02 April 2008
MILAN, ITALY (UroToday.com) - Sorafenib is an oral multi-kinase inhibitor that has demonstrated efficacy in metastatic renal cell carcinoma (MRCC). The pleiotropic molecule interferon-α2a (IFN) has anti-angiogenic activity that is thought to be dependent on an appropriate administration schedule. These investigators studied the activity and safety of sorafenib combined with IFN in two different schedules.
Login to read more...
|
EAU 2008 - Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma (mRCC)
Wednesday, 02 April 2008
MILAN, ITALY (UroToday.com) - Updated results and analysis of prognostic factors from a phase III randomized trial.
Login to read more...
|
EAU 2008 - Elective Nephron-Sparing Surgery for Renal Masses
Tuesday, 01 April 2008
MILAN, ITALY (UroToday.com) - Comparison of Open and Laparoscopic Approach in a Bi-Center Analysis
Login to read more...
|
EAU 2008 - Surgical Management - Risk Factor Analysis of Post-Operative Complications in Laparoscopic Partial Nephrectomy
Tuesday, 01 April 2008
MILAN, ITALY (UroToday.com) - Dr.Turna from the group of Dr. Gill at the Cleveland Clinic presented their experience with laparoscopic partial nephrectomy (LPN) to determine risk factors for postoperative complications.
Login to read more...
|
EAU 2008 - Urological Research Society (URS) Lecture: Surgical Strategies in Advanced RCC
Tuesday, 08 April 2008
MILAN, ITALY (UroToday.com) - The URS lecture covered the topic of surgical strategies in advanced renal cell carcinoma (RCC). Especially the questions of routine adrenalectomy, management of intravasal tumor thrombus and surgery of metastases were raised.
Login to read more...
|
EAU 2008 - Management of Advanced Renal Cell Carcinoma (Brain Metastases) with Sorafenib
Monday, 31 March 2008
MILAN, ITALY (UroToday.com) - Results from the ARCCS expanded access program
Login to read more...
|
Conference Coverage 
